Comparative Pharmacology
Head-to-head clinical analysis: CARDIOLITE versus DRAXIMAGE MDP 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIOLITE versus DRAXIMAGE MDP 10.
CARDIOLITE vs DRAXIMAGE MDP-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium Tc-99m sestamibi is a lipophilic cation that accumulates in myocardial cells via passive diffusion across the sarcolemmal and mitochondrial membranes. Its uptake is proportional to myocardial blood flow and viability, allowing for imaging of myocardial perfusion.
Technetium-99m medronate is a bone-seeking radiopharmaceutical that localizes in areas of bone turnover, binding via chemisorption to hydroxyapatite crystals, allowing scintigraphic imaging of skeletal lesions.
CARDIOLITE (Technetium-99m sestamibi) is administered intravenously. For myocardial perfusion imaging, adult dose: 10-40 mCi (370-1480 MBq), administered as a single bolus.
555-1110 MBq (15-30 mCi) intravenously for skeletal imaging; administered 2-3 hours before imaging.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; prolonged in elderly and renal impairment (up to 12-16 hours).
Terminal elimination half-life: 2.5 hours (range 2-3 hours); clinically, allows rapid imaging post-injection.
Renal: 85-90% as unchanged drug; fecal: <5%
Renal: 95% within 6 hours; biliary/fecal: <5%.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical